Antidiabetic agents and their hypothetical benefit on the risk of cardiac arrhythmias - 17/11/22

Plan
| Funding: none |
|
| Conflict of interest: LF has served as a consultant or speaker for AstraZeneca, Bayer, BMS/Pfizer, Boehringer Ingelheim, Novartis, Novo and Zoll. |
Vol 48 - N° 6
Article 101406- novembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
